CS1-CAR-T targeting the proximal C2 domain of CS1 (antibody clone HuLuc63 [8]); demonstrated anti-myeloma activity in preclinical models [12, 13] and is being pursued in clinical trials although results are not currently published. This evidence concerns the gene SLAMF7 and plasma cell myeloma.